Neuro-developmental follow-up of neonates treated with magnesium sulfate for persistent pulmonary hypertension

Journal of Neonatal-Perinatal Medicine

Volumn 1, Issue 2, 2008, Pages 83-91

  Galli, S ^a   Bickle Graz, M ^a   Forcada Guex, M ^a   Muehlethaler, V ^a   Jaunin, L ^a   Tolsa, J F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Magnesium sulfate; Neuro developmental follow up; Persistent pulmonary hypertension of the newborn

Indexed keywords

EID: 85013571363     PISSN: 19345798     EISSN: 18784429     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Y.K.Abu-Osba, O. Galal, K. Manasra and A. Rejjal, Treatment of severe persistent pulmonary hypertension of the newborn with magnesium sulphate, Arch Dis Child 67 (1992), 31-35.
2. American Psychiatric Association. DSM-IV Manuel diagnostique et statistique des troubles mentaux. Masson, 1994.
3. C. Amiel-Tison, A method for neurologic evaluation within the first year of life, Curr Probl Pediatr 7 (1976), 1-50.
4. R.A. Ballard and C.H. Leonard, Developmental follow-up of infants with persistent pulmonary hypertension of the newborn, Clin Perinatol 11 (1984), 737-744.
5. A.J. Bennett, N.J. Shaw, J.E. Gregg and N.V. Subhedar, Neurodevelopmental outcome in high-risk preterm infants treated with inhaled nitric oxide, Acta Paediatr 90 (2001), 573-576.
6. J.C. Bernbaum, P.H. Sheridan, M.H. Gewitz, W.W. Fox and G.J. Peckham, Long-term follow-up of newborns with persistent pulmonary hypertension, Crit Care Med 12 (1984), 579-583.
7. E.M. Bifano and A. Pfannenstiel, Duration of Hyperventilation and Outcome in Infants With Persistent Pulmonary Hypertension, Pediatrics 81 (1988), 657-661.
8. S. Chandran, M. Haqueb, H.T.Wickramasinghec and Z.Wint, Use of Magnesium Sulphate in Severe Persistent Pulmonary Hypertension of the Newborn, J Trop Pediatr 50 (2004), 219-223.
9. P.Y. Cheung, M.M. Haluschak, N.N. Finer and C.M.T. Robertson, Sensorineural hearing loss in survivors of neonatal extracorporeal membrane oxygenation, Early Hum Dev 44 (1996), 225-233.
10. R.S. Cohen, D.K. Stevenson, N. Malachowski, R.L. Ariagno, J.D. Johnson and P. Sunshine, Late morbidity among survivors of respiratory failure treated with tolazoline, Pediatrics 97 (1980), 644-647.
11. Committee on Fetus and Newborn, Use of Inhaled Nitric Oxide, Pediatrics 106 (2000), 344-345.
12. G.J.A. Cropp, Reduction of hypoxic pulmonary constriction by magnesium chloride, J Appl Physiol 24(1968), 755-760.
13. C.A. Crowther, J.E. Hiller, L.W. Doyle and R.R. Haslam, Effect of Magnesium Sulfate Given for Neuroprotection Before Preterm Birth: A Randomized Controlled Trial, JAMA 290 (2003), 2669-2676.
14. S.H. Daffa and W.A. Milaat, Role of magnesium sulphate in treatment of severe persistent pulmonary hypertension of the neoborn, Saudi Med J 23 (2002), 1266-1269.
15. S.R. Daga, D.V. Gosavi, B. Verma and V.K. Ahuja, Magnesium sulphate for management of pulmonary hypertension in non-ventilated newborns, J Trop Pediatr 46 (2000), 52-53.
16. H.H. de Haan, A.J. Gunn, C.E.Williams, M.A. Heymann and P.D. Gluckman, Magnesium sulfate therapy during asphyxia in near-term fetal lambs does not compromise the fetus but does not reduce cerebral injury, Am J Obst Gynecol 176 (1997), 18-27.
17. Jr. M. Ellington, D. O’Reilly, E.N. Allred, M.C. McCormick, D.L. Wessel and S. Kourembanas, Child Health Status, Neurodevelopmental Outcome, and Parental Satisfaction in a Randomized, Controlled Trial of Nitric Oxide for Persistent Pulmonary Hypertension of the Newborn, Pediatrics 107 (2001), 1351-1356.
18. W.J. Fawcett, D.J. Haxby and D.A. Male, Magnesium: Physiology and pharmacology, Br J Anaesth 83 (1999), 302-320.
19. B. Ferrera, D.E. Johnson, C. Pi-Nian and T.R. Thompson, Efficacy and neurologic outcome of profound hypocapneic alkalosis for the treatment of persistent pulmonary hypertension in infancy, Pediatrics 105 (1984), 457-461.
20. P. Glass, A.E. Wagner, P.H. Papero, S.R. Rajasingham, L.A. Civitello, M.S. Kjaer, C.E. Coffman and B.L. Short, Neurodevelopmental status at age five years of neonates treated with extracorporeal membrane oxygenation, Pediatrics 127 (1995), 447-457.
21. L.J. Graziani, M. Gringlas, S. Baumgart, Cerebrovascular complications and neurodevelopmental sequelae of neonatal ECMO, Clin Perinatol 24 (1997), 655-675.
22. K. Greenwood, P. Cox, H. Mehmet, J. Penrice, P.N. Amess, E.B. Cady, J.S. Wyatt and A.D. Edwards, Magnesium Sulfate Treatment after Transient Hypoxia-Ischemia in the Newborn Piglet Does Not Protect against Cerebral Damage, Ped Res 48 (2000), 346-350.
23. R. Griffifths, The Abilities of Babies. University of London Press ed. 1970.
24. K.D. Hendricks-Munoz and J.P. Walton, Hearing Loss in Infants With Persistent Fetal Circulation, Pediatrics 81 (1988), 650-656.
25. J.J.R.G. Ho, Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2007, John Wiley & Sons, Ltd.
26. H. Ichiba, T.Yokoi, H. Tamai, T. Ueda, T. Kim and T.Yamano, Neurodevelopmental outcome of infants with birth asphyxia treated with magnesium sulfate, Pediatr Int 48 (2006), 70-75.
27. H. Ichiba, S. Matsunami, F. Itoh, T. Ueda, Y. Ohsasa and T. Yamano, Three-year follow up of term and near-term infants treated with inhaled nitric oxide, Ped Int 45 (2003), 290-293.
28. J.P. Kinsella and S.H. Abman, Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn, Pediatrics 126 (1995), 853-864.
29. G.G. Konduri, New approaches for persistent pulmonary hypertension of newborn, Clin Perinatol 31 (2004), 591-611.
30. R.H. Largo, D. Pfister, L.Molinari, S. Kundu, A. Lipp and G. Duc, Significance of prenatal, perinatal, and postnatal factors in the development of AGA preterm infants at five to seven years, Dev Med Child Neurol 31 (1989), 440-456.
31. A.M. Leavitt and J.F.Watchko, Neurodevelopmental outcome following persistent pulmonary hypertension of the neonate, J Perinatol 7 (1987), 288-291.
32. M. Levene, M. Blennow, A. Whitelaw, E. Hanko, V. Fellman and R. Hartley, Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia, Arch Dis Child -Fetal Neonatal Ed 73 (1995), F174-F177.
33. A. Leviton, N. Paneth, M. Susser, Má. Reuss, E.N. Allred and K. Kuban, Maternal Receipt of Magnesium Sulfate Does Not Seem to Reduce the Risk of Neonatal White Matter Damage, Pediatrics 99 (1997), e2.
34. P.H. Lipkin, D. Davidson, L. Spivak, R. Straube, J. Rhines and C.T. Chang, Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide, Pediatrics 140 (2002), 306-310.
35. S. Marret, L. Marpeau, V. Zupan-Simunek, D. Eurin, C. Leveque, M.F. Hellot and J. Bénichou, PREMAG trial group, Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*, Br J Obstet Gynaecol 114 (2007), 310-318.
36. M.J. Marron, M.A. Crisafi, J.M.Jr. Driscoll, J.T. Wung, Y.T. Driscoll, T.H. Fay and L.S. James, Hearing and Neurodevelopmental Outcome in Survivors of Persistent Pulmonary Hypertension of the Newborn, Pediatrics 90 (1992), 392-396.
37. R. Mathew, B.T. Altura and B.M. Altura, Strain differences in pulmonary hypertensive response to monocrotaline alkaloid and the beneficial effect of oral magnesium treatment, Magnesium 8 (1989), 110-116.
38. D. McCarthy, Manual for the McCarthy Scales of Children’s Abilities, Psychological Corporation, New York, NY, 1972.
39. R. Mittendorf, J. Dambrosia, P.G. Pryde, K.S. Lee, J.G. Gianopoulos, R.E. Besinger and P.G. Tomich, Association between the use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants, Am J Obstet Gynecol 186 (2002), 1111-1118.
40. R. Mittendorf and P.G. Pryde, A review of the role for magnesium sulphate in preterm labour, Br J Obstet Gynaecol 112 (2005), 84-88.
41. P.M. Nair and M.F. Bataclan, Persistent pulmonary hypertension of the newborn, Saudi Med J 25 (2004), 693-699.
42. F. Raimondi, F. Migliaro, L. Capasso, G. Ausanio, M. Bisceglia, P. Giliberti, F. Messina, G. Salvia and R. Paludetto, Intravenous Magnesium sulphate vs. Inhaled Nitric Oxyde for Moderate, Persistent Pulmonary Hypertension of the Newborn. A Multicentre, Retrospective Study, J Trop Ped 2007 (Epub ahead of print)
43. C.M.T. Robertson, M.T. Juzer, A. Peliowski, C.E. Philip and P.Y. Cheung, Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure, Acta Paediatrica 95 (2006), 214-223.
44. A.A. Rosenberg, J.M. Kennaugh, S.G. Moreland, L.M. Fashaw, K.A. Hale, F.M. Torielli, S.H. Abman and J.P. Kinsella, Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension, Pediatrics 131 (1997), 70-75.
45. H. Sameshima and T. Ikenoue, Long-term magnesium sulfate treatment as protection against hypoxic-ischemic brain injury in seven-day-old rats, Am J Obstet Gynecol 184 (2001), 185-190.
46. R.E. Schumacher, T.W. Palmer, D.W. Roloff, P.A. LaClaire and R.H. Bartlett, Follow-up of Infants Treated With Extracorporeal Membrane Oxygenation for Newborn Respiratory Failure, Pediatrics 87 (1991), 451-457.
47. E.J. Sell, J.A. Gaines, C. Gluckman and E.Williams, Persistent fetal circulation. Neurodevelopmental outcome, ArchPed Adol Med 139 (1985), 25-28.
48. M. Sheridan, Manual for the Stycar vision test, National Foundation for Educational Research, 1960.
49. The Neonatal Inhaled Nitric Oxide Study Group*, Inhaled nitric oxide in term and near-term infants, Neurodevelopmental follow-up of The Neonatal Inhaled Nitric Oxide Study Group (NINOS), Pediatrics 136 (2000), 611-617.
50. J.F. Tolsa, J. Cotting, N. Sekarski, M. Payot, J.L. Micheli and A. Calame, Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn, Arch Dis Child - Fetal Neonatal Ed. 72 (1995), F184-F187.
51. J.F.Tolsa, Y. Gao and J.U. Raj, Developmental change in magnesium sulfate-induced relaxation of rabbit smooth muscle arteries, J Appl Physio 87 (1999), 1589-1594.
52. B. Touwen, The examination of the child with minor neurological dysfunction, Clinics in developmental medicine, Heinemann, London 71, 1979.
53. M.C.Walsh-Sukys, J.E. Tyson, L.L. Wright, C.R. Bauer, S.B. Korones, D.K. Stevenson, J. Verter, B.J. Stoll, J.A. Lemmons, L.A. Papile, S.Shankaran, E.F. Donovan, W.Oh, R.A. Ehrenkranz and A.A. Fanaroff, Persistent Pulmonary Hypertension of the Newborn in the Era Before Nitric Oxide: Practice Variation and Outcomes, Pediatrics 105 (2000), 14-20.
54. B. Weinberger, K. Weiss, D.E. Heck, D.L. Laskin and J.D. Laskin, Pharmacologic therapy of persistent pulmonary hypertension of the newborn, Pharmacol Therap 89 (2001), 67-79.
55. S.R. Wildin, S.H. Landry and J.B. Zwischenberger, Prospective, Controlled Study of Developmental Outcome in Survivors of Extracorporeal Membrane Oxygenation: The First 24 Months, Pediatrics 93 (1994), 404-408.
56. T.J. Wu, R.J. Teng and K.I. Tsou, Persistent Pulmonary Hypertension of the Newborn Treated With Magnesium Sulfate in Premature Neonates, Pediatrics 96 (1995), 472-474.